Patents Examined by Kimberly Chong
  • Methods and compositions for managing vascular conditions using miR-483 mimics and HIF1alpha pathway inhibitors
    Patent number: 11225660
    Abstract: This disclosure relates to the use of miRNA-483 and its target genes, UBE2C, pVHL and HIF1alpha, in managing the treatment of cardiovascular and inflammatory diseases. In certain embodiments, this disclosure relates to pharmaceutical compositions comprising a miR-483 mimic and/or an HIF inhibitor and a pharmaceutically acceptable excipient for use in treating or preventing a vascular disease or condition. In certain embodiments, the miR-483 mimic is a double stranded nucleobase polymer or an expression vector that expresses mature human miR-483-5p and miR-483-3p sequences or operable fragments and variants.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: January 18, 2022
    Assignee: Emory University
    Inventors: Hanjoong Jo, Joan Fernandez Esmerats, Nicolas Villa-Roel
  • Formulation
    Patent number: 11220690
    Abstract: The present invention relates to a new formulation of the oligonucleotide of SEQ ID NO:1.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: January 11, 2022
    Assignee: Atlantic Pharmaceuticals (Holdings) LTD
    Inventors: Toby Wilson Waterworth, Lorin Johnson, Janette Thomas, Michael Webb
  • Bi-specific aptamer
    Patent number: 11219635
    Abstract: Provided are aptamers and aptamer compositions and particularly, although not exclusively, to a bi-specific aptamer capable of binding a tumor cell antigen and an immune cell surface protein.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: January 11, 2022
    Assignees: City of Hope, Apterna Limited
    Inventors: John J. Rossi, Sorah Yoon, Nagy Habib
  • MicroRNAs as biomarkers for endometriosis
    Patent number: 11220713
    Abstract: Disclosed herein are compositions and methods useful for the diagnosis, assessment, and characterization of endometriosis in a subject in need thereof, based upon the expression level of at least one miRNA that is associated with endometriosis.
    Type: Grant
    Filed: February 25, 2021
    Date of Patent: January 11, 2022
    Assignee: Yale University
    Inventor: Hugh Taylor
  • Circulating microRNA signatures for ovarian cancer
    Patent number: 11214839
    Abstract: Provided herein are methods and kits for determining the presence or absence of certain microRNA biomarkers in a blood sample of a female patient. The microRNA biomarkers are associated with ovarian cancer. Also provided are methods for screening a female subject for the presence or absence of certain microRNA biomarkers, as well as methods for treating a female subject having an ovarian cancer.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: January 4, 2022
    Assignees: DANA-FARBER CANCER INSTITUTE, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC., MEDICAL UNIVERSITY OF LODZ
    Inventors: Dipanjan Chowdhury, Kevin M. Elias, Wojciech Fendler, Konrad Stawiski
  • Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure
    Patent number: 11208657
    Abstract: The invention provides a method for generating an oligonucleotide with which an exon may be skipped in a pre-mRNA and thus excluded from a produced mRNA thereof. Further provided are methods for altering the secondary structure or an mRNA to interfere with splicing processes and uses of the oligonucleotides and methods in the treatment of disease. Further provided are pharmaceutical compositions and methods and means for inducing skipping of several exons in a pre-mRNA.
    Type: Grant
    Filed: December 10, 2019
    Date of Patent: December 28, 2021
    Assignee: Academisch Ziekenhuis Leiden
    Inventor: Judith C. Van Deutekom
  • Coronavirus iRNA compositions and methods of use thereof
    Patent number: 11208660
    Abstract: The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the coronavirus genome. The invention also relates to methods of using such RNAi agents to inhibit expression of a coronavirus genome and to methods of treating or preventing a coronavirus-associated disease in a subject.
    Type: Grant
    Filed: May 17, 2021
    Date of Patent: December 28, 2021
    Assignees: Alnylam Pharmaceuticals, Inc., Vir Biotechnology, Inc.
    Inventors: Akin Akinc, James D. McIninch, Yesseinia Anglero-Rodriguez, Mark K. Schlegel, Christy M. Hebner, Florian A. Lempp
  • High-efficiency transfection of biological cells using sonoporation
    Patent number: 11198878
    Abstract: A method is provided for achieving transfection of host cells using sonoporation. An acoustic radiation generator is positioned in acoustic coupling relationship with respect to a reservoir containing host cells to be transfected, exogenous material to be incorporated into the host cells, and a cell-compatible fluid medium. The acoustic radiation generator is activated to generate acoustic radiation and direct the acoustic radiation into the reservoir in a manner effective to enable transfection of the host cells with the exogenous material.
    Type: Grant
    Filed: August 28, 2020
    Date of Patent: December 14, 2021
    Assignee: LABCYTE INC.
    Inventors: Jennifer M. Hardee, Richard N. Ellson, Richard G. Stearns, Babur Hadimioglu, Joseph D. Olechno, Marsha N. Blauwkamp
  • Combinations for the modulation of SMN expression
    Patent number: 11198867
    Abstract: Certain embodiments are directed to methods and compounds for modulating expression of SMN. In certain embodiments at least two compounds are used: a first compound for inhibiting SMN-NAT and increasing expression of SMN, and a second compound for modulating the splicing of SMN. Such methods and compounds are useful for increasing expression exon 7 containing SMN mRNA in cells and animals.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: December 14, 2021
    Assignees: Ionis Pharmaceuticals, Inc., The Johns Hopkins University
    Inventors: Frank Rigo, C. Frank Bennett, Constantin Van Outryve D'Ydewalle, Charlotte J. Sumner
  • Modulation of the notch signaling pathway for treatment of respiratory disorders
    Patent number: 11197884
    Abstract: Provided herein are methods, compounds, and compositions for modulating expression of at least one member of the Notch signaling pathway in a cell or individual. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a respiratory disorder associated with excessive mucus production in an individual.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: December 14, 2021
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventor: Tamar R. Grossman
  • CTLA-4 aptamer conjugates
    Patent number: 11186840
    Abstract: Provided herein are, inter alia, nucleic acid compounds useful for targeting CTLA-4-expressing cells and modulating cell activity of the CTLA-4-expressing cells. The compositions provided herein may be part of pharmaceutical compositions and may be used for treatment of cancer, inflammatory diseases, infectious diseases or metabolic diseases.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: November 30, 2021
    Assignee: CITY OF HOPE
    Inventors: Hua Yu, Andreas Herrmann, Marcin Tomasz Kortylewski
  • Methods of treatment of cancer with reduced UBB expression
    Patent number: 11179413
    Abstract: The present invention provides compositions comprising a UBC antagonist and methods of use thereof for treating cancer in a patient. In some embodiments, the cancer patient may have a reduced expression level of a UBB gene product. Further provided are reagents and methods for detection of a UBB and/or UBC gene product.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: November 23, 2021
    Assignee: NOVARTIS AG
    Inventors: William C. Forrester, Alexia T. Kedves-Volpe
  • Nucleic acid-polypeptide compositions and methods of inducing exon skipping
    Patent number: 11179472
    Abstract: Disclosed herein are molecules and pharmaceutical compositions that induce an insertion, deletion, duplication, or alteration in an incorrectly spliced mRNA transcript to induce exon skipping or exon inclusion. Also described herein include methods for treating a disease or disorder that comprises a molecule or a pharmaceutical composition that induces an insertion, deletion, duplication, or alteration in an incorrectly spliced mRNA transcript to induce exon skipping or exon inclusion.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: November 23, 2021
    Assignee: AVIDITY BIOSCIENCES, INC.
    Inventors: Arthur A. Levin, Andrew John Geall, Venkata Ramana Doppalapudi, Michael Caramian Cochran, Hanhua Huang, Rob Burke
  • Dry powder composition comprising long-chain RNA
    Patent number: 11179337
    Abstract: The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.
    Type: Grant
    Filed: November 11, 2019
    Date of Patent: November 23, 2021
    Assignee: CureVac AG
    Inventors: Fabian Johannes Eber, Benyamin Yazdan Panah, Stefanie Sewing, Thomas Ketterer, Thorsten Mutzke, Tilmann Roos, Michael Sonntag, Michael Wiggenhorn, Katharina Kolland
  • Placenta-derived adherent cell exosomes and uses thereof
    Patent number: 11173182
    Abstract: Provided herein are compositions of placenta-derived adherent cell exosomes and methods of making and using the same. In one aspect, provided herein are compositions comprising exosomes produced by and/or derived from placental cells, e.g., placenta-derived adherent cells. In certain embodiments, the exosomes provided herein are produced by placenta-derived adherent cells that have been cultured in vitro for, e.g., 1, 2, 3, 4, 5, 6 or more passages.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: November 16, 2021
    Assignee: Celularity Inc.
    Inventors: Eric Law, Andrew Morschauser, Aleksander Francki, Jennifer Paredes, Kathy Karasiewicz-Mendez, Allan Reduta, Vladimir Jankovic, Ivana Djuretic, Robert J. Hariri
  • HNF4A saRNA compositions and methods of use
    Patent number: 11162099
    Abstract: The invention relates to saRNA targeting an HNF4a transcript and therapeutic compositions comprising said saRNA. Methods of using the therapeutic compositions are also provided.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: November 2, 2021
    Assignee: MINA THERAPEUTICS LIMITED
    Inventors: Hans E. Huber, David Blakey, Jon Voutila, Monika Krampert, Markus Hossbach
  • Double-stranded RNA molecule targeting CKIP-1 and use thereof
    Patent number: 11155819
    Abstract: The present invention relates to the field of biomedicine, particularly to double-stranded RNA molecules targeting CKIP-1 and uses thereof, particularly to use of the double-stranded RNA molecules for the treatment of inflammatory diseases such as arthritis, particularly rheumatoid arthritis.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: October 26, 2021
    Assignee: BEIJING TIDE PHARMACEUTICAL CO., LTD.
    Inventors: Yanping Zhao, Hongjun Wang, Yuanyuan Jiang, Weiting Zhong, Jianmei Pang, Gong Li, Xiang Li, Yixin He, Liying Zhou, Yanan Liu
  • Conjugation of lipophilic albumin-binding moiety to RNA for improved carrier-free in vivo pharmacokinetics and gene silencing
    Patent number: 11147827
    Abstract: Provided herein are compounds and methods for gene silencing. The compound includes a RNA directly conjugated to an albumin-binding group. The method includes administering a compound comprising a RNA directly conjugated to an albumin-binding group to a subject in need thereof.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: October 19, 2021
    Assignee: Vanderbilt University
    Inventors: Craig L. Duvall, Samantha M. Sarett, Thomas A. Werfel
  • Antisense antibacterial compounds and methods
    Patent number: 11142764
    Abstract: Provided are antisense oligomers targeted against bacterial mRNAs and other macromolecules associated with a biochemical pathway and/or cellular process, and related compositions and methods of using the oligomers and compositions to treat an infected mammalian subject, for example, as primary antimicrobials or as adjunctive therapies with classic antimicrobials.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: October 12, 2021
    Assignees: Board of Regents, The University of Texas System, Oregon State University
    Inventors: David Greenberg, Bruce L. Geller
  • Antisense oligonucleotides that bind to exon 51 of human dystrophin pre-mRNA
    Patent number: 11142767
    Abstract: The present invention relates to a therapeutic antisense oligonucleotide which binds to exon 51 of the human dystrophin pre-mRNA to induce exon skipping, and conjugates and compositions thereof for the treatment of DMD.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: October 12, 2021
    Assignee: THE GOVERNORS OF THE UNIVERSITY OF ALBERTA
    Inventors: Toshifumi Yokota, Yusuke Echigoya